# Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)

> **NCT00255034** · PHASE4 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 146 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **BIOLOGICAL:** Peginterferon alfa-2b
- **BIOLOGICAL:** Peginterferon alfa-2b
- **DRUG:** Ribavirin
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00255034
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-02
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 146 (ACTUAL)
- **Why stopped:** Recruitment targets were unachievable in the currently available population.
- **Last updated:** 2017-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00255034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00255034, "Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00255034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*